Lucinda Bateman

2016-10-27T13:28:33Z

Jevaner:change a sentence about "International Consensus Criteria".

[[File:LucindaBateman.jpeg|right]]
'''Lucinda Bateman''' (Cindy Bateman), MD, is an [[ME/CFS]] doctor and researcher. She founded and is Chief Medical Officer of the [[Bateman Horne Center]] of Excellence for ME/CFS and Fibromyalgia in Salt Lake City, Utah. <ref>https://batemanhornecenter.org/</ref>

Dr. Bateman was one of the authors of the 2011 case definition, [[International Consensus Criteria]],<ref name="Carruthers, 2011"/>, but pulled back lateron, after the dramatic "Dear Cindy" letter from Suzanne Vernon - and was one of the experts on the "Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome" that was convened for the 2015 [[Institute of Medicine report]].<ref>http://www.ncbi.nlm.nih.gov/books/NBK284904/</ref>

[[Suzanne Vernon]], PhD, the Research Liaison at [[Bateman Horne Center]] of Excellence works closely with Dr. Bateman on [[ME/CFS]] and [[fibromyalgia]] research.<ref>https://batemanhornecenter.org/suzanne-d-vernon-phd/</ref>

==Open Letter to ''The Lancet''==
Two [[open letter to the Lancet | open letters to the editor of ''The Lancet'']] urged the editor to commission a fully independent review of the [[PACE]] trial, which the journal had published in 2011. In 2016, Dr. Bateman, along with 41 colleagues in the [[ME/CFS]] field, signed the second letter.
*10 February 2016, [http://www.virology.ws/2016/02/10/open-letter-lancet-again/ An open letter to The Lancet, again - Virology blog]

==Notable studies==
*2015, Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome. [http://www.tandfonline.com/doi/full/10.1080/21641846.2015.1023652 Abstract]<ref>Klimas, N. G., Ironson, G., Carter, A., Balbin, E., Bateman, L., Felsenstein, D., ... & Cunningham, K. (2015). Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome. ''Fatigue: Biomedicine, Health & Behavior, 3'' (2), 75-96. doi:10.1080/21641846.2015.1023652</ref>
*2015, Chronic fatigue syndrome and co-morbid and consequent conditions: evidence from a multi-site clinical epidemiology study. [http://www.tandfonline.com/doi/full/10.1080/21641846.2014.978109 Abstract]<ref>Bateman, L., Darakjy, S., Klimas, N., Peterson, D., Levine, S. M., Allen, A., ... & March, D. (2015). Chronic fatigue syndrome and co-morbid and consequent conditions: evidence from a multi-site clinical epidemiology study. ''Fatigue: Biomedicine, Health & Behavior, 3'' (1), 1-15. doi:10.1080/21641846.2014.978109</ref>
*2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.<blockquote>Abstract: "A Phase III prospective, double-blind, randomized, placebo-controlled trial comparing twice weekly IV rintatolimod versus placebo was conducted in 234 subjects with long-standing, debilitating CFS/ME at 12 sites. The primary endpoint was the intra-patient change from baseline at Week 40 in exercise tolerance (ET). Secondary endpoints included concomitant drug usage, the Karnofsky Performance Score (KPS), Activities of Daily Living (ADL), and Vitality Score (SF 36). Subjects receiving rintatolimod for 40 weeks improved intra-patient placebo-adjusted ET 21.3% (p = 0.047) from baseline in an intention-to-treat analysis. Correction for subjects with reduced dosing compliance increased placebo-adjusted ET improvement to 28% (p = 0.022). The improvement observed represents approximately twice the minimum considered medically significant by regulatory agencies. The rintatolimod cohort vs. placebo also reduced dependence on drugs commonly used by patients in an attempt to alleviate the symptoms of CFS/ME (p = 0.048). Placebo subjects crossed-over to receive rintatolimod demonstrated an intra-patient improvement in ET performance at 24 weeks of 39% (p = 0.04). Rintatolimod at 400 mg twice weekly was generally well-tolerated.<ref name="Strayer, 2012"/></blockquote>

==Clinic location==
[https://batemanhornecenter.org/ The Bateman Horne Center]
1002 E. South Temple St., Suite 408, Salt Lake City, Utah 84102
1-801-359-7400

==Talks & interviews==
*2016, [https://www.youtube.com/watch?v=ru8o-n-u_Ts Simple But Effective Tools for Management of ME/CFS and FM - Lucinda Bateman, MD]
*2016, [https://www.youtube.com/watch?v=kXTt_JFDQ5w&feature=em-subs_digest BHC Wings to Fly - Dr. Bateman]
*2015, [[Spoonie Radio]] Episode 10 Guest - Dr. Lucinda Bateman - [http://www.drcourtneycraig.com/blog/2015/5/6/spoonie-radio-ep-10-dr-lucinda-bateman Podcast and Full Text Transcript]

==Webinars ==

'''Science to patients / Wetenschap voor patienten'''

*2015, [https://youtu.be/1TogkD07tHA 68. Introduction and diagnosis / intriductie en diagnose - Dr. Lucinda Bateman]

*2015, [https://youtu.be/HiiLYbCzfIM 69. Autoimmunity in ME/cfs / Auto-immuniteit bij ME/cvs - Dr. Lucinda Bateman]

*2015, [https://youtu.be/la3HQtoJWzE 70. Neuroinflammation and ME/cfs / Neuro-inflammatie en ME/cvs - Dr. Lucinda Bateman]

*2015, [https://youtu.be/OZ39Jy9Z9QI 71. ME/cfs and the Brain/ ME/cvs en de hersenen - Dr. Lucinda Bateman]

*2015, [https://youtu.be/F1PP21TmUPs 72. Gene-expression and exercise / gen-expressie en inspanning - Dr. Lucinda Bateman]

*2015, [https://youtu.be/p70hBlLgtaI 73. FAQs part 1 / Veel gestelde vragen deel 1 - Dr. Lucinda Bateman]

*2015, [https://youtu.be/QuXO8RCjyWQ 74. FAQs part 2 / Veel gestelde vragen deel 2 - Dr. Lucinda Bateman]

'''Solve ME/CFS Initiative'''

*[https://www.youtube.com/watch?v=359XmpNBHM8 Apr 17, 2015 "Will SEID Diagnostic Criteria Improve Diagnosis and Treatment?"]
*[https://www.youtube.com/watch?v=w4OEGOCw3Dg&feature=youtu.be Nov 14, 2014 "Can ME CFS and Fibromyalgia Research Help You Sleep?"]

==Online presence==
*[https://www.ncbi.nlm.nih.gov/pubmed/?term=Bateman+Lucinda%5BAuthor%5D PubMed - Lucinda Bateman]
*[https://twitter.com/LBatemanMD Twitter]
*Facebook
*Website
*YouTube

==Learn more==
*[http://www.cortjohnson.org/chronic-fatigue-syndrome-mecfs-doctor-resource-center/dr-lucinda-bateman/ Cort Johnson - Lucinda Bateman profile]
*[https://batemanhornecenter.org/drlucindabateman/ Lucinda Bateman]

==See also==
*[[Bateman Horne Center]]
*[[Suzanne Vernon]]

==References==
<references>
<ref name="Carruthers, 2011">
{{Citation
| last1 = Carruthers | first1 = BM | authorlink1 = Bruce Carruthers
| last2 = van de Sande | first2 = MI | authorlink2 = Marjorie van de Sande
| last3 = De Meirleir | first3 = KL | authorlink3 = Kenny de Meirleir
| last4 = Klimas | first4 = NG | authorlink4 = Nancy Klimas
| last5 = Broderick | first5 = G | authorlink5 = Gordon Broderick
| last6 = Mitchell | first6 = T | authorlink6 = Terry Mitchell
| last7 = Staines | first7 = D | authorlink7 = Donald Staines
| last8 = Powles | first8 = A C P | authorlink8 = A C Peter Powles
| last9 = Speight | first9 = N | authorlink9 = Nigel Speight
| last10 = Vallings | first10 = R | authorlink10 = Rosamund Vallings
| last11 = Bateman | first11 = L | authorlink11 = Lucinda Bateman
| last12 = Baumgarten-Austrheim| first12 = B | authorlink12 = Barbara Baumgarten-Austrheim
| last13 = Bell | first13 = DS | authorlink13 = David Bell
| last14 = Carlo-Stella | first14 = N | authorlink14 = Nicoletta Carlo-Stella
| last15 = Chia | first15 = J | authorlink15 = John Chia
| last16 = Darragh | first16 = A | authorlink16 = Austin Darragh
| last17 = Jo | first17 = D | authorlink17 = Daehyun Jo
| last18 = Lewis | first18 = D | authorlink18 = Donald Lewis
| last19 = Light | first19 = A | authorlink19 = Alan Light
| last20 = Marshall-Gradisnik | first20 = S | authorlink20 = Sonya Marshall-Gradisnik
| last21 = Mena | first21 = I | authorlink21 = Ismael Mena
| last22 = Mikovits | first22 = JA | authorlink22 = Judy Mikovits
| last23 = Miwa | first23 = K | authorlink23 = Kunihisa Miwa
| last24 = Murovska | first24 = M | authorlink24 = Modra Murovska
| last25 = Pall | first25 = ML | authorlink25 = Martin Pall
| last26 = Stevens | first26 = S | authorlink26 = Staci Stevens
| title = Myalgic encephalomyelitis: International Consensus Criteria.
| journal = Journal of Internal Medicine | volume = 270 | issue = 4 | page = 327-38
| date = 2011
| pmid = 21777306
| doi = 10.1111/j.1365-2796.2011.02428.x
}}
</ref>

<ref name="Strayer, 2012">
{{Citation
| last1 = Strayer | first1 = DR | authorlink1 = David Strayer
| last2 = Carter | first2 = WA | authorlink2 = William Carter
| last3 = Stouch | first3 = BC | authorlink3 =
| last4 = Stevens | first4 = SR | authorlink4 = Staci Stevens
| last5 = Bateman | first5 = L | authorlink5 = Lucinda Bateman
| last6 = Cimoch | first6 = PJ | authorlink6 =
| last7 = Lapp | first7 = CW | authorlink7 =Charles Lapp
| last8 = Peterson | first8 = DL | authorlink8 = Daniel Peterson
| last9 = Chronic Fatigue Syndrome AMP-516 Study Group | authorlink9 =
| last10 = Mitchell | first10 = WM | authorlink10 = William Mitchell
| title = A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.
| journal = PLoS One | volume = 7 | issue = 3 | page = e31334
| date = 2012
| pmid = 22431963
| doi = 10.1371/journal.pone.0031334
}}
</ref>

<references/>

[[Category:Researchers]]
[[Category:USA researchers]]
[[Category:Clinicians]]
[[Category:American clinicians]]
[[Category:Utah clinicians]]

MEpedia - User contributions [en]

Lucinda Bateman